The Russian Immune Diversity Atlas project aims to profile immune cells from people of different ancestries at a multiomics level. The goal is to reconstruct a reference atlas of the healthy immune system and investigate its perturbations in Type II Diabetes (T2D). The project seeks to identify novel mechanisms and genetic/epigenetic markers for early T2D diagnostics, prognosis, and therapy as part of the international Human Cell Atlas. Why it matters: Addressing genetic diversity in biomedical research, particularly in the context of the Human Cell Atlas, is crucial for personalized medicine and ensuring that treatments are effective across diverse populations in the Middle East and globally.
KAUST researchers have discovered the first molecular events that trigger wheat's immunity to stem rust, a devastating fungal disease. The study, published in Science, identifies that tandem kinases are bound together and inactive until a pathogen binds, initiating an immune response that kills the infected cell. This prevents the pathogen from spreading and causing widespread crop damage. Why it matters: Understanding these molecular mechanisms could lead to engineering wheat with stronger and more durable resistance to stem rust and other diseases, safeguarding a crucial food source in the face of climate change and emerging pathogens.
KAUST researchers are analyzing the SARS-CoV-2 genome to identify potential targets for treatment and vaccine development. They are using the KAUST Metagenome Analysis Platform (KMAP) and the university's supercomputer to compare and analyze genomic data. The research focuses on identifying key genes for detection and treatment of COVID-19. Why it matters: This research contributes to the global effort to combat the pandemic and highlights KAUST's capabilities in genomic data analysis and computational bioscience.
KAUST researchers have discovered that a coral's resilience to rising temperatures is determined by the microorganisms living inside them. The study identifies specific combinations of microeukaryotes and bacteria that enhance heat resistance in corals. This finding provides valuable clues for developing coral probiotics to protect and restore coastal reefs. Why it matters: This breakthrough could lead to effective interventions to combat coral bleaching and preserve vital marine ecosystems in the Red Sea and beyond.
KAUST Professor Hernando Ombao is leading the Biostatistics Group to develop statistical models for projecting hospitalization surges during the COVID-19 pandemic. The group uses techniques like time series analysis and stationary subspace analysis to understand complex biological processes. The models aim to provide public health officials with accurate hospitalization estimates under varying scenarios. Why it matters: This research contributes to preparedness and resource allocation in healthcare systems during public health crises, with potential applications beyond COVID-19.
KAUST researchers suggest antibody testing can complement PCR tests to reduce false negatives in COVID-19 diagnosis. PCR tests can produce false negative results. Immunodiagnostic tests could help identify unknowingly spreading the disease. Why it matters: Improving diagnostic accuracy is critical for effective pandemic control and public health management in Saudi Arabia and globally.
MBZUAI's Professor Le Song is developing an AI-driven simulation to model the human body at societal, organ, tissue, cellular, and molecular levels. The goal is to reduce the time and cost associated with bringing new medicines to market by removing the need for wet lab biological research. Song aims to create a comprehensive model using machine learning. Why it matters: This research could revolutionize drug discovery in the region by accelerating the development process and reducing reliance on traditional research methods.
SaudiVax, located in the KAUST Research & Technology Park, is collaborating with the University of Pittsburgh and Merck France to develop a COVID-19 antibody injection. The antibody both protects against potential infection and neutralizes the virus in those already infected. SaudiVax is utilizing KAUST expertise and has contracted with Merck France for manufacturing since suitable facilities are not yet available in Saudi Arabia. Why it matters: This partnership highlights the growing biopharmaceutical capabilities in Saudi Arabia and the potential for KAUST to serve as a hub for medical innovation in the region.